2 terminated. 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Terminated 2 |
Follow Endocyte: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Lutetium-177 (Lu177) Prostate-Specific Antigen (PSMA)-Directed EndoRadiotherapy 177Lu-PSMA-617 - Metastatic Castration Resistant Prostate Cancer | Phase 2 | Terminated | Endocyte | 71 | 2017-07-12 | 2021-03-24 |
| A Phase II Study of EC17 (Folate-hapten Conjugate) in Patients With Progressive Metastatic Renal Cell Carcinoma EC90 (KLH-FITC), GPI-0100, EC17 (Folate-FITC) - Renal Cell Carcinoma | Phase 2 | Terminated | Endocyte | 12 | 2007-06-01 | 2012-03-08 |
Carcinoma, Renal Cell (1) · Neoplasm Metastasis (1) · Neoplasms (1)
GPI0100 (1) · Interferon-alpha (1) · Interleukin-2 (1) · Introns (1) · Pluvicto (1) · aldesleukin (1) · fluorescein isothiocyanate-keyhole limpet hemocyanin (1)
United States (2)
Richard A Messmann, MD, MHS, BSc (1)